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Abstract 
Purpose: To design, formulate and characterize sustained-release formulations of dexketoprofen 
trometamol (DT) nanoparticles (NPs) 
Methods: Dexketoprofen trometamol (DT)-loaded poly(lactic-co-glycolic acid) (PLGA) NPs were 
produced by double emulsion-solvent evaporation method. The NPs were variously characterized for 
drug loading and release, particle profile, as well as by thermal analysis, x-ray difraction (XRD), Fourier 
transform infrared spectroscopy (FTIR) and nuclear magnetic resonance analysis (1H-NMR). 
Furthermore, the NPs were evaluated for cytotoxicity against NIH-3T3 cells by 3-(4,5-dimethylthiazol-2-
Yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Results: The DT-loaded NPs demonstrated nanostructural characteristics and extended drug release. 
Particle size was in the range of 243 and 295 nm which remained unchanged in drug stability testing in 
simulated gastrointestinal media. Encapsulation efficiency ranged from 49 – 64 % for all the 
formulations. Higuchi and Korsmeyer-Peppas were the best-fit release kinetic models for the NPs 
containing 5 and 10 % DT, respectively. The NPs with 10 % DT presented no significant cytotoxicty at 
the doses and periods studied.  
Conclusion: Stable and non-toxic DT NPs with potential for sustained and controlled release of the 
drug have been successfully developed. 
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The ability to manage and treat pain continues to 
be one of the most common clinical objectives of 
practitioners. Pain has a very important effect on 
the biological, psychological, sociological and 
economic dispositions of a patient [1]. Non-
steroidal anti-inflammatory drugs (NSAIDs), 
skeletal muscle relaxants and opioid analgesics 
are among the most prescribed drugs for pain 
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[2]. The NSAIDs block a group of physiological 
proteins called cyclooxygenase (COX) which are 
invoved in the production of prostaglandins and 
thromboxanes responsible for pain and 
inflammation [3].  
 
Ketoprofen, a member of the arylpropionate 
group of NSAIDs has well-defined analgesic and 
anti-inflammatory effects. Racemic ketoprofen is 
used as an analgesic and anti-inflammatory 
agent, and it is one of the most potent inhibitors 
of prostaglandin synthesis in vitro [4]. 
Dexketoprofen trometamol (DT) was developed 
as a water-soluble trometamine. İt is a rapidly-
acting analgesic agent in the treatment of painful 
musculoskeletal disorders such as back pain and 
osteoarthritis [5]. 
 
Polymeric nanoparticles (PNPs) are being 
extensively investigated as drug delivery systems 
worldwide for pharmaceutical applications. They 
provide modified release of drugs for extended 
periods of time [6]. The most commonly used 
biodegradable polymers in the production of 
polymeric NPs for modified release are 
polyglycolic acid, polylactic acid and their 
copolymers, e.g., PLGA (polylactic-co-glycolic 
acid) [7].  
 
Modified drug release can be obtained by 
polymeric NPs owing to different properties of 
PLGA used [8]. Polyglycolic acid is a hydrophilic 
agent and dissolves readily in intracellular 
conditions. Polylactic acid is more hydrophobic 
than polyglycolic acid due to an additional methyl 
group in the side chain; and therefore 
biodegradation takes place much longer than 
polyglycolic acid [9]. Double emulsion techniques 
are commonly used for the encapsulation of 
hydrophilic molecules with low encapsulation 
efficiency because of rapid drug partitioning into 
the external aqueous phase in classical 
emulsions. In double emulsification technique, 
displacement of a lipophilic solvent with a water-
miscible semi-polar solvent results in 
accumulation of polymer on the surface. Rapid 
diffusion of the non-solvent reduces the 
interfacial tension between the two phases 
leading to an increase in surface area and thus 
formation of small organic solvent droplets. It is a 
very simple and economic method [10]. 
Surveying extant patents and publications, some 
modified release formulations and locally 
available commercial preparations of DT were 
found [11-13].  
 
The present study was carried out to design, 
formulate and characterize sustained-release 






Dexketoprofen trometamol was a kind gift from 
Abdi İbrahim (İstanbul/Turkey). Poly(lactic-co-
glycolic acid) (PLGA) (Resomer® RG 504 H) was 
obtained from Evonik Industries (Germany). 
Polyvinil alcohol (PVA) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA), while ethyl 
acetate and sodium acetate trihydrate were 
obtained from Panreac Química (Barcelona, 
Spain). Methanol was from Merck (Gradient 
grade for liquid chromatography, Darmstadt/ 
Germany). Deionized and filtered water was 
used in all experiments (Milli-Q Academic, 
Millipore, Molsheim, France). All other chemicals 
used were of analytical grade. 
 
Preparation of PLGA nanoparticles  
 
The PLGA NPs were prepared by ‘Double 
Emulsification Solvent Evaporation Technique’ 
[14]. Weighed amount of PLGA was dissolved in 
ethyl acetate to obtain a concentration of 40 
mg/mL. Then, 100 µL aqueous solution of PVA 
(0.5 % w/v) was added drop-wise to 2 mL PLGA 
solution using ultrasonic bath (1 minute, JP 
Selctra) (W1/O). Two mL of this emulsion was 
then added drop-wise to 10 mL of PVA aqueous 
solution (0.5 %, w/v) using high-speed 
homogenizer (Polytron PT 2500 E) at 24.000 rpm 
for 1 min (W1/O/W2). The ethyl acetate was 
evaporated at room temperature in 4 h to obtain 
an aqueous dispersion which was finally 
centrifuged to obtain the NPs (11.000 rpm, 30 
min, and 4 °C; Eppendorf 504R, Eppendorf AG, 
Hamburg, Germany). For the preparation of DT-
loaded PLGA NPs, the procedure was started by 
adding 4 - 8 mg DT [5 % DT (Alp-5) and 10 % DT 
(Alp-10)] to 100 µL aqueous solution of PVA (0.5 
% w/v). The aqueous solution of PVA containing 
100 µL DT was added drop-wise to 2 mL PLGA 
solution in an ultrasonic bath (1 min, JP Selctra) 
(W1/O). Two mL of this emulsion was then added 
drop-wise to 10 mL of PVA aqueous solution (0.5 
%, w/v) under high-speed homogenizer (Polytron 
PT 2500 E) at 24.000 rpm for 1 min (W1/O/W2). 
The ethyl acetate was evaporated at room 
temperature in 4 h to obtain an aqueous 
dispersion which was finally centrifuged to obtain 
the NPs (11,000 rpm, 30 min, 4 °C; Eppendorf 
504R, Eppendorf AG, Hamburg, Germany).  
 
Determination of particle size, PDI, zeta 
potential and morphology 
 
Particle size (PS) and PDI were measured on 
freshly prepared samples using Malvern analyzer 
(Zetamaster 3000, Malvern Instruments Ltd., 
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UK). Samples of all PLGA NPs were diluted with 
distilled water prior to analysis. All analyses were 
repeated three times at room temperature. 
Surface electrical charge (zeta potential) of 
PLGA NPs was characterized by laser Doppler 
electrophoresis (Zetamaster 3000, Malvern 
Instruments Ltd, UK). Measurements were 
repeated three times at room temperature. 
Morphological and structural characteristics of 
the PLGA NPs prepared were investigated using 
SEM (Hitachi TM 3030 Plus, Japan). Lyophilized 
samples were coated with thin layer of gold using 
a coater (Karaltay Scientific Instruments, China) 
under 50 mA for 30 seconds before observation 
under a scanning electron micoscope (SEM). 
 
Assessment of cryoprotectant effect on 
PLGA NPs 
 
Some experiments were carried out on Alp-5 and 
Alp-10 formulations to determine storage and 
lyophilization conditions. Following PS 
measurement of fresh formulations, they were 
centrifuged and the supernatants were 
discarded. The resulting particles were added to 
1 mL of 5 % (w/v) trehalose solution and the PS 
measurement was performed again. The 
dispersion was then divided into 10 equal 
portions in 10 eppendorf tubes numbered 1 - 10. 
While no trehalose solution was added to tubes 1 
and 2, 100 µL, 200 µL, 300 µL and 400 µL 
trehalose solution (5 % w/v) were added to tubes 
3 and 4; 5 and 6; 7 and 8; 9 and 10, respectively 
(i.e. in duplicates). All formulations were then 
frozen at -20 °C prior to PS analysis after melting 
tubes 1, 3, 5, 7 and 9 at room temperature. 
Following lyophilization (Telstar® CRYODOS, 
Liofilizador de Laboratorio, Spain) of tubes 2, 4, 
6, 8 and 10, the dry particles were removed from 
the lyophilizer and dispersed in 1 mL of water, 
followed by PS analysis. 
 
Evaluation of stability of PLGA NPs 
 
The NPs prepared using hydrolytic degradable 
polymers are known to degrade over time. 
Effects of pH and temperature have a very 
significant effect on long-term stability [15]. 
Before testing the stability of PLGA NPs, 
solutions simulating gastrointestinal fluids were 
prepared. The solutions were pepsin-free HCl 
(pH 1.2, Solution 1), pepsin-containing HCl 
solution (pH 1.2, Solution 2, 0.32 % pepsin, w/v); 
intestinal fluid phosphate buffer solution (Solution 
3, pH 6.8); phosphate buffer solution (Solution 4, 
pH 7.4); physiological serum (0.9 % NaCl) 
solution (Solution 5) and Milli-Q water.  
 
All five solutions and Milli-Q water were placed in 
a shaking water bath at a stirring speed of 40 
rpm at a temperature of 37 ºC to simulate the 
gastric medium. One set of formulations (Alp-5 
and Alp-10) was prepared and dispersed in 
trehalose solution at 5 % (w/v) concentration. 
Then, 1 mL of this dispersion was added to 
solutions incubated at 37±1°C. Samples were 
collected after preincubation periods of 1, 2, 3, 4, 
5, 6, 7 and 24 h and centrifuged at 4.000 rpm for 
5 min to precipitate NPs. Finally, the average 





The amount of DT loaded into PLGA NPs and 
dissolution study of each formulation was 
performed using HPLC (Shimadzu Corporation, 
Kyoto, Japan) with reversed-phase Symetry® and  
C18 (5.0  µm, 250 mm x 4.6 mm, Symmetry US) 
column. In the HPLC system, the mobile phase 
was methanol:acetate buffer (65:35 v/v) mixture, 
the flow rate was 0.9 mL.min-1, while detection 
was performed at 242 nm at 40°C. Injection 
volume and run time were 25 µL and 12 min, 
respectively. Mobile phase was prepared daily, 
de-gassed by sonication and filtered through 
0.45 µm membrane filter before the experiment. 
The method was validated for precision, 
accuracy, specificity and linearity [16]. 
 
Evaluation of entrapment efficiency  
 
The loading of DT into PLGA NPs was 
determined by reverse phase-HPLC (RP-HPLC) 
method as described earlier. The DT content of 
PLGA NPs was assessed directly by extracting 
DT from NPs. Lyophilized NPs (about 5 mg) 
were weighed, 1 mL ethyl acetate was added 
and the mixture was vortexed to dissolve the 
particles in the organic phase. All solutions were 
filtered through 0.22 µm polyamid filter prior to 
analysis with HPLC system. The DT content was 
expressed as encapsulation efficiency (EE) as in 
Eq 1. 
 
EE (%) = {(W1-W2)/W1}100 ......... (1) 
 
where W1 is the actual amount of DT loaded into 
PLGA NPs and W2 is the theoretical amount of 
DT loaded into PLGA NPs. 
 
In vitro dissolution studies 
 
The ability of the PLGA formulations to release 
DT in the stomach (pH 1 or 1.2), small intestine 
(pH 6.8) and colon (pH 7.4) was assessed by 
release studies in simulated gastric and intestinal 
media [17]. In vitro release profiles from PLGA 
NPs were investigated over 10 days using a 
dialysis membrane. PLGA NPs equivalent to 10 
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mg DT was placed in a cellulose acetate dialysis 
bag with a molecular weight of 12-14 kDa 
(Sigma). After sealing the two ends, in vitro 
release study was started in 75 mL 0.1 N 
hydrochloric acid (pH 1.0) at 37 °C with stirring at 
100 rpm using a magnetic stirrer.  
 
The study was carried out for 2 h, and then 
continued at pH 6.8 (obtained by addition of 25 
mL 0.2 M tribasic sodium phosphate solution) for 
the next 3 h, and thereafter at pH 7.4 (obtained 
by addition of 5 mL 0.2 M tribasic sodium 
phosphate solution) for the remaining time 
intervals. Stirring was maintained at 100 rpm and 
temperature at 37 ± 0.5 °C in all media. Samples 
were collected at certain intervals and replaced 
with the same volume of fresh dissolution 
medium. The samples were then analyzed using 
HPLC method. 
 
Determination of in vitro release kinetics 
 
Data obtained in the in vitro drug release studies 
were further investigated for release kinetics 




Thermal analysis of the NPs prepared was 
carried out using DSC (Schimadzu DSC-60, 
Japan) in a pressure-assisted aluminum sample 
vessel at a nitrogen gas flow rate of 50 mL·min-1 
and a temperature increase rate of 10°C·min-1 at 




The NPs were subjected to XRD analysis 
performed with a Rikagu generator (XRD Rikagu 
Rint 2000, Japan) at a speed of 40 kV, current 
intensity of 30 mA, angle of 2Ɵ and speed of 




The FT-IR spectra of the NPs prepared were 
determined by FT-IR (Schimadzu IR Prestige-21, 





The PLGA NPs were subjected to NMR analysis 
(1H-NMR). They were collected by centrifugation, 
lyophilized and dissolved in deutero chloroform 
(CDCl3) prior to analysis using NMR (Bruker 500 
MHz UltraShield NMR, Germany). 
 
 
Cell culture  
 
Mouse embryonic fibroblast cells (NIH/3T3) were 
selected for culture studies. The cells were 
grown in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10 % fetal bovine 
serum (Sigma Aldrich, Germany), 2 mM L-
glutamine and penicillin-streptomycin (Sigma 
Aldrich, Germany) at 37 °C in a humidified 




Quantitative cell cytotoxicity was determined by 
colorimetric MTT (3-(4, 5-dimethyl thiazol-2yl)-2, 
5-diphenyl tetrazolium bromide) assay. Briefly, 
cells removed from the flask were seeded in 96-
well plates and left to incubate for 24 h. At the 
end of the incubation period, fresh growth media 
containing different concentrations of NPs were 
added to the wells to give final concentrations in 
the range 5 -1000 µg/mL. The plates were re-
incubated for another 24 - 48 h, and MTT dye 
was added at end of each incubation time. The 
resultant formazan crystals were dissolved with 
DMSO, and the absorbance of solution was read 
at 572 nm in a microplate reader (BioTek 
Cytation5, Germany) [19]. The results obtained 
were expressed as percentage inhibition relative 
to control cells where cell survival was taken as 





Each experiment was carried out three 
independent times and the data are presented as 
mean ± standard deviation (SD).  Microsoft Excel 





Particle size, polydispersity index and zeta 
potential 
 
The size and size distribution of PLGA NPs 
measured by laser scattering method are 
presented in Table 1. All data obtained from six 
independent experiments were expressed as the 
mean diameter and standard deviation (SD) 
values. Figure 1 shows SEM images of the 
prepared PLGA NPs. The images revealed 
regular and symmetrical morphology.  
 
Effect of cryoprotectant on PLGA NPs 
 
Figure 2 shows the effect of cryoprotectant 
addition on Alp-5 and Alp-10 NP sizes and size 
distributions. 
Ozturk et al 
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Table 1: Particle size, PDI, zeta potential and entrapment efficiency of DT nanoparticles (mean ± SD) 
 
Code PS (nm)  PDI  ZP (mV)  EE % ± SD 
Alp-blank 295.7 ± 2.9 0.101 ± 0.015 -29.59 ± 0.23 - 
Alp-5 243.8 ± 5.3 0.062 ± 0.024 -27.26 ± 0.92 64.194 ± 0.484 
Alp-10 251.9 ± 2.8 0.075 ± 0.020 -26.48 ± 0.63 49.239 ± 1.129 




Figure 1: Scanning electron micrographs of PLGA 




Figure 2: Effect of cryoprotectant on particle size 
distribution of nanoparticles prepared. PS: Particle 
size; *: fresh formulation after centrifugation and 
dispersing in 1 mL trehalose solution (5 % w/v) 
 
Stability of PLGA NPs 
 
Figure 3 shows NP sizes in MilliQ water, pepsin-
free HCl solution, pH 1.2;, pepsin-containing HCl 
solution, pH 1.2;, intestinal fluid phosphate 
buffer, pH 6.8;  phosphate buffer, pH 7.4, and 




The HPLC method used in the study was 
validated for precision, accuracy, specificity and 
linearity. Linearity was at a concentration range 
of 9.375 - 250 µg.mL-1. The method for DT was 
precise due to RSD values of <2 % for 
repeatability and intermediate precision. 
Recovery of the method was satisfactory owing 
to < 2 % RSD value. The DT showed a linearity 
of y = 17901x + 1890.4 (r2 = 0.999), and 
accuracy of 100.103 ± 0.203, 100.094 ± 0.123 
and 99.658 ± 0.521 % for 25, 100 and 150 
µg.mL-1, respectively (n=6). The limit of detection 
(LOD) was 0.0002 µg.mL-1, while the limit of 




Figure 3: Stability test in different media, a: Alp-5, b 
Alp-10, PS: nm range 
 
Entrapment efficiency (EE) 
 
The EE % values of NPs loaded with DT are 
given in Table 1. 
 
In vitro dissolution  
 
The DT release profiles from PLGA NPs are 
shown in Figure 4. The release of DT continued 
over 10 days while pure DT exhibited a rapid 
release of 99.087 % in 1 day. The release values 
observed from Alp-5 and Alp-10 formulations 
after 10 days were 75.976 % and 92.156 %, 
respectively, demonstrating modified release 
from both formulations, relative to pure DT. 
 
In vitro release kinetics  
 
Kinetic modeling of DT release from PLGA NPs 
is shown in Table 2. In this study, DDSolver 
computer program was used to shorten the 
calculation time, eliminate calculation errors and 
determine the correct release profile. After 
obtaining the release profiles, data were 
transferred to the DDSolver program to 
determine the four most important and popular 
criteria: coefficient of determination (Rsqr, R2, or 
COD), adjusted coefficient of determination 
(Rsqr_adj or R2adjusted), Akaike Information 
Criterion (AIC) and Model Selection Criterion 
(MSC). The highest R2, R2adjusted and MSC values 
Ozturk et al 
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and the lowest AIC values were used for 
evaluating zero-order kinetics, first-order kinetics, 
Higuchi, and Korsmeyer-Peppas models [18]. 
The R2, R2adjusted, MSC and AIC obtained are 




Figure 4: In vitro dissolution profiles of pure DT and 




Thermal analysis (DSC) results of pure DT, Alp-
blank, Alp-5 and Alp-10 PLGA NPs obtained in 
the determination of the physical state of DT in 
NPs are given in Figure 5. The melting 
endothermic peak of pure DT which appeared at 
105.1°C disappeared in thermograms of Alp-5 




Figure 5: Thermogram of a: pure DT, b: PLGA, c: 




The XRD profiles of pure DT, pure polymers, 
physical mixture and the formulations prepared 
are given in Figure 6. The XRD profiles of all 
prepared NPs had no DT crystal peaks. In 





The FT-IR analysis results are shown in Figure 7. 
The IR spectrum of PLGA polymer exhibited 
molecular vibrations of its different functional 
groups as shown in Figure 8. Carbonyl groups 
observed between 1770 cm-1 and 1750 cm-1 with 
intense bands may be attributed to the stretching 
vibration of the carbonyl groups present in the 
two monomers. 
 
Medium intensity bands between 1300 cm-1 and 
1150 cm-1 show asymmetric and symmetric C-
C(=O)-O streches, respectively, which are 
distinctive bands often used for the characteriza-
Table 3:  Kinetic release data 
 
Formulation Model and equation Evaluation criteria R2 R2adjusted AIC MSC 
Alp-5 Zero-order model* F=k0*t 
0.696 0.696 149.253 1.019 
Alp-10 Zero-order model* F=k0*t 
0.675 0.675 158.618 1.087 
Alp-5 First-order model* F=100*[1-Exp(-k1*t)] 
0.793 0.793 140.688 1.470 
Alp-10 First-order model* F=100*[1-Exp(-k1*t)] 0.850 0.850 145.222 1.792 
Alp-5 Higuchi model* F=kH*t0.5 
0.968 0.968 105.219 3.336 
Alp-10 Higuchi model* F=kH*t0.5 
0.978 0.978 108.897 3.704 
Alp-5 Korsmeyer-Peppas* Model F=kKP*tn 
0.922 0.917 101.942 2.338 
Alp-10 Korsmeyer-Peppas* Model F=kKP*tn 0.986 0.985 124.182 4.070 
*F: fraction (%) of drug released in time t, k0: zero-order release constant, k1: first-order release constant, kH: 
Higuchi release constant, kKP: release constant incorporating structural and geometric characteristics of drug-
dosage form, n: diffusional exponent indicating drug-release mechanism 
 
Ozturk et al 




Figure 6: X-ray diffractograms of a: DT, b: PLGA, c: 
physical mixture, d: Alp-blank, e: Alp-5, f: Alp-10 
 
tion of esters. Stretching vibrations of the OH 
group at 3500 cm-1 and 3450 cm-1 refer to 
lactides and glycolides. According to the 
literature, DT is characterized by an intense band 
at 1020 cm−1. Vibrations at 1571 cm−1, 1536 
cm−1, 1020 cm−1, 881 cm−1, 771 cm−1 and 641 




The 1H-NMR spectra of pure DT, pure PLGA 
(Resomer® 504 H) and blankempty/loaded PLGA 
NPs are shown in Figure 8.  It is known that 
PLGA (Resomer® RG 504H) contains two types 
of structural units: the most intense signals of CH 
(5.16 ppm) and CH3 (1.44 ppm) from lactic acid 
and CH2 (4.88 ppm) from glycolic acid. The CH2 
hydrogens were diastrotopic and divided into 
two, ending in two pairs of peaks which were 
assigned for both protons. Higher CH2, CH3 and 
CH signals in the copolymer caused those peaks 
to expand. Specific peaks of DT in 1H-NMR 
spectrum were observed at 1.45 (d, 3H) ppm, 
3.64 (s, 6H) ppm, 3.66 (q, 1IH) ppm and 7.41-




Figure 7: FTIR spectra of, a: DT, b: PLGA, c: Alp-




Figure 8. 1H-NMR spectra of a: DT, b: PLGA, c: Alp- 
empty, d: Alp-5, and e: Alp-10 
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Cytotoxicity of nanoparticles 
 
In vitro cytotoxicity testing is important in 
assessing biocompatibility of new formulations to 
ensure absence of acute toxicity response or risk 
for patients. The cell viabilities at various DT 
concentrations are shown in Figure 9. From the 
results obtained, the IC50 values in wells treated 
with DT only were 750 µg/mL and 250 µg/mL at 
24 and 48 h, respectively. Alp-blank did not 
reduce cell viability below 88 % even at the 
highest dose applied. Alp-10 formulation showed 
69 and 55 % cell viabilities after 24 and 48 h, 




Figure 9: Cell viability of PLGA NP formulations 





Nanosized particles determined with 243.8 - 
295.7 nm sizes can be attributed to the 
hydrophobicity of the polymer used. Small 
particle sizes were obtained using polymers with 
high molecular weight and high hydrophobicity 
due to longer aliphatic chains. It is also known 
that low particle sizes are obtained as a result of 
preparation conditions (24.000 rpm, 1 min) [21]. 
The 10 % DT-incorporated particles appeared to 
have bigger sizes when compared to other DT-
loaded particles.  
 
Polydispersity index (PDI) indicates the range of 
particle size distribution, and PDI values in the 
range of 0 - 1 demonstrate homogeneous 
distribution when it approaches zero. Very low 
PDI values of prepared formulation indicate 
homogeneous particle size distribution [13,20].  
Zeta potential (ZP) values of PLGA NPs were 
found to be negative most probably due to the 
total negative charges of the functional groups on 
PLGA. Studies have shown that NPs with a ZP 
value of about +/-30 mV are stable in suspension 
due to prevention of particles from accumulating 
[20]. 
 
Freeze-drying (lyophilization) is a popular and 
preferred procedure for increasing the stability of 
various pharmaceutical products [14]. Since NPs 
may increase in size during freezing and drying 
steps, special agents must be added to the 
suspension before freezing to protect them. The 
most popular cryoprotectants for freeze-dried 
NPs are sugar derivatives, eg trehalose, sucrose, 
glucose and mannitol [20]. In this study, 
trehalose was used at different concentrations 
and the sizes of nanoparticles were measured 
after freezing in the refrigerator to determine the 
optimum concentration of the cryoprotectant. 
Usually, the level of cryoprotectant used ranges 
from 0 to 50 % by weight, which is solubilized 
directly in NPs suspension immediately prior to 
freeze-drying [14]. Particle sizes seem to be 
similar for all trehalose concentrations. The NP 
size was increased at low concentration of 
trehalose and therefore 1 mL trehalose solution 
was found to be adequate for keeping the 
particle size constant after freeze-drying. 
 
The stability of NPs was tested at 37°C in 
different media for better understanding of in vitro 
release profiles. After incubation for 24 h at 37°C 
in MilliQ water and all other solutions, average 
sizes of NPs did not change significantly, when 
compared to the first particle size measured. The 
results obtained indicate slow degradation of 
NPs in all media at 37°C, which also provides 
preliminary information for selection of 
dissolution medium [14]. 
 
Drug loading capacity of NPs is an important 
factor in formulations because higher loading 
leads to lower amount of NPs for a given dose. 
With respect to the amount of DT initially used (5 
% and 10 % w/w), EE % was found to decrease 
as the DT concentration increased. This means 
that the maximum amount which can be 
entrapped in the polymer matrix i.e. miscibility of 
the polymer with the active substance is limited 
[14]. The remaining drug may migrate to the 
surrounding emulsifier aqueous phase. If the 
surfactant used to stabilize the emulsion is 
present at a concentration higher than the critical 
micelle concentration, surfactant micelles can 
solubilize the drug, which may reduce 
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encapsulation efficiency [33]. The findings 
obtained in this study support this hypothesis. As 
a result, formulations with a high EE % were 
produced and the EE % was decreased by 
increasing the amount of agent. 
 
Two main release mechanisms associated with 
drug release from PLGA nanoparticle systems 
are diffusion and degradation/erosion. It has 
been reported that drug release rate is initially 
controlled by diffusion followed by 
degredation/erosion [22]. There seems to be an 
inverse relationship between amount of drug 
released and particle size. It was reported 
previously that large microspheres degrade 
faster than small microspheres. This is probably 
due to the increased accumulation of acidic 
products during polymer hydrolysis in large 
microspheres where hydrolysis starts 
immediately in PLGA systems.  
 
Further catalysis of hydrolysis by the acids 
produced during the initial hydrolysis ie the 
autocatalytic process leads to a more rapid 
degradation at the center of the PLGA matrix 
than from the surface. This effect becomes more 
pronounced as the size of the nanoparticle 
system increases [22]. Alp-10 formulation with a 
larger particle size probably degrades relatively 
faster than Alp-5 formulation, leading to a higher 
release. A biphasic profile consisting of a rapid 
phase followed by a slow release phase was 
observed for DT from PLGA NPs.  
 
An Excel add-in DDSolver program which allows 
modeling of dissolution data was designed by 
researchers to reduce computation time and 
eliminate computational errors [18]. Higuchi 
model was the most appropriate kinetic model for 
DT release from Alp-5 formulation while the best 
fit of Alp-10 formulation was to the Korsmeyer-
Peppas model. This difference may be attributed 
to different loading efficiencies (% EE) and 
localization of the active agent in different 
regions within the polymer. 
 
The disappearance of endothermic DT peak in 
DSC thermograms of all PLGA NPs indicates 
incorporation of DT, homogenous matrix 
formation and amorphous structure [13]. The 
characteristic melting peak of DT was seen in the 
thermogram of physical mixture which can also 
be considered as an indicator of the amorphous 
state of DT in the formulations [23]. 
The technique of XRD is a well-defined analytical 
method frequently used in research because it 
clarifies molecular structure of nanoparticles, 
examines crystal state, investigates 
polymorphism and also provides information 
about stability [18]. The absence of DT crystal 
peaks in XRD profiles of all prepared NPs 
demonstrated amorphous nanoparticle formation 
and DT dispersion in polymeric matrix at the 
molecular level which may be due to the dilution 
effect [42]. Disappearance of DT peaks in XRD 
profiles of NPs suggest absence of high 
superficial adsorption and occurence of 
incorporation [20,23]. 
 
Infrared spectroscopy analysis is important and 
is used frequently to determine the chemical 
composition and regulation of binding of 
components to homo-polymer, co-polymer, 
polymer composite, polymeric materials and 
nanotechnology [44]. It was observed that the 
characteristic DT peaks disappeared or 
appeared with very low intensity in the spectra of 
PLGA nanoparticles prepared. This indicates that 
DT was molecularly dispersed and incorporated 
into the polymeric structure, which is consistent 
with the results from DSC and XRD [23]. 
 
Physicochemical properties of nanoparticles, 
interaction of active ingredients with 
polymers/additives and molecular mobility can be 
determined by NMR analysis [49]. When the 
results of the analysis were evaluated, it was 
seen that there was no significant difference 
between the spectra of empty formulation and 
that of pure PLGA. This shows clearly that  there 
was no structural change due to the effect of 
other substances or preparation conditions. 
Lowered DT peaks at 7-8 ppm in the spectra of 
Alp-5 and Alp-10 PLGA NPs suggest DT 
incorporation into PLGA polymer, as well as 
molecular distribution of DT in the polymeric 
matrix [13,20,23]. 
 
In this study, time and dose-dependent MTT 
experiments were performed to detect living cells 
depending on the degree of activation of the 
signaling cells produced  [13]. The PLGA NPs 
are the most preferred delivery systems due to 
their sustainability, degradability and better 
loading capacity. It has been reported previously 
that no significant cytotoxicity is observed with 
PLGA even at high concentrations [24].  In this 
study, the high IC50 (> 1250 µg/mL after 72 h 
incubation) determined for the empty formulation 
without DT shows the safety of the polymer and 
other excipients used for NP preparation. 
Literature survey showed only one study on the 
cytotoxicity of DT which reported high toxicity 
depending on time and concentration. İncreased 
cytotoxicity due to application of DT alone to the 
wells was observed in a previous study 
performed by the present research group [13]. 
However, PLGA NPs containing DT 
demonstrated 55 % cell viability even at the 
highest concentration. Thus, PLGA NPs were 
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This study shows that DT loaded PLGA NPs can 
be prepared successfully by double emulsion 
solvent evaporation method. The particle size of 
the NPs obtained were in the nanometer range 
and remained constant in the short-term GI 
stability testing. The nanoparticle formulation did 
not show significant cytotoxicity at dose- and 
time-dependent considerations. Thus, it is 
considered appropriate for drug delivery 
purposes. The DT-loaded PLGA NPs are stable 
and represent a promising system for sustained 
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